journal article·2012-11Open access

Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity

Peng Guo, Jin-Oh You, Jiang Yang, Marsha A. Moses, Debra T. Auguste

Biomaterials· Volume 33· Issue 32

Abstract

The primary cause of mortality in breast cancer is tumor aggressiveness, characterized by metastases to regional lymph nodes, bone marrow, lung, and liver. C-X-C chemokine receptor type 4 (CXCR4) has been shown to mobilize breast cancer cells along chemokine gradients. Quantification of CXCR4 surface expression may predict the efficacy of anti-CXCR4 labeled liposomal therapeutics to target and kill breast cancer cells. We evaluated gene and surface receptor expression of CXCR4 on breast cancer cell lines distinguished as having low and high invasiveness, MDA-MB-175VII and HCC1500, respectively. CXCR4 surface expression did not correlate with invasiveness. MDA-MB-175VII exhibited more binding to anti-CXCR4 labeled liposomes relative to HCC1500. Increased binding correlated with greater cell death relative to IgG labeled liposomes. Quantitative cell characterization may be used to select targeted therapeutics with enhanced efficacy and minimal side effects.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Chemokine receptors and signaling · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (37)

Show source-provided references
1. Cancer statistics
2. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up10.1093/annonc/mdq160 ↗
3. The detection and diagnosis of early, occult and minimal breast cancer
4. Breast cancer metastasis: markers and models10.1038/nrc1670 ↗
5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER210.1056/NEJM200103153441101 ↗
6. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women10.1200/JCO.1998.16.10.3439 ↗
7. Lapatinib plus capecitabine for HER2-positive advanced breast cancer10.1056/NEJMoa064320 ↗
8. Efficacy and Safety of Trastuzumab as a Single Agent in First-line treatment of HER2-Overexpressing metastatic breast cancer10.1200/JCO.2002.20.3.719 ↗
9. Involvement of chemokine receptors in breast cancer metastasis10.1038/35065016 ↗
10. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists10.1126/science.1194396 ↗
11. Opinion: the CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies10.1038/nrc1473 ↗
12. Topoisomerase-targeting antitumor drugs
13. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin10.1021/bi00462a016 ↗
14. Liposomal doxorubicin10.3109/10611869609015970 ↗
15. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab10.1038/nature01392 ↗
16. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells10.1158/0008-5472.CAN-04-1168 ↗
17. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase10.1158/0008-5472.CAN-03-2868 ↗
18. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues10.3816/CBC.2004.n.011 ↗
19. Targeted drug delivery via the transferrin receptor-Mediated Endocytosis pathway10.1124/pr.54.4.561 ↗
20. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives10.1111/j.1745-7254.2007.00681.x ↗
21. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm10.1182/blood-2003-08-2807 ↗
22. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace10.1016/j.biocel.2007.03.002 ↗
23. Complementary targeting of liposomes to IL-1α and TNF-α activated endothelial cells via the transient expression of VCAM1 and E-selectin10.1016/j.biomaterials.2011.08.093 ↗
24. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation10.1021/mp9003095 ↗
25. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes10.1016/j.biomaterials.2009.09.107 ↗
26. Ammonium sulfate gradients for efficient and Stable Remote loading of Amphipathic Weak Bases into liposomes and Ligandoliposomes10.3109/08982109409037057 ↗
27. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer10.1016/j.tips.2009.08.004 ↗
28. Molecular Profiling of breast cancer cell lines Defines Relevant tumor models and Provides a Resource for cancer gene Discovery10.1371/journal.pone.0006146 ↗
29. CXCR4 Regulates growth of both primary and metastatic breast cancer10.1158/0008-5472.CAN-04-1844 ↗
30. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling10.1089/scd.2008.0235 ↗
31. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages10.1073/pnas.96.9.5215 ↗
32. Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates10.1016/j.bbmt.2004.07.002 ↗
33. Deciphering the fluorescence signature of daunomycin and doxorubicin10.1016/S0301-4622(98)00150-1 ↗
34. Bioresponsive matrices in drug delivery
35. Nanocarrier Cross-Linking density and pH Sensitivity Regulate intracellular gene transfer10.1021/nl902789s ↗
36. The effect of swelling and cationic character on gene transfection by pH-sensitive nanocarriers10.1016/j.biomaterials.2010.04.048 ↗
37. Feedback-regulated paclitaxel delivery based on poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles10.1016/j.biomaterials.2007.12.041 ↗